Drugs / lefitolimod
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02668770 | May 2016 → Nov 2025 | high grade malignant neoplasm, melanoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT01982747 | Nov → Dec 2013 | — | Mologen AG | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04357821 | Aug 2020 → Jun 2026 overdue | HIV infectious disease | University of California, San Francisco | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02443935 | Apr 2015 → Jun 2017 | HIV infectious disease | University of Aarhus | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02200081 | Mar 2014 → Nov 2016 | small cell lung carcinoma | Mologen AG | Completed | Missed primary |
| Phase 2 | NCT01208194 | Jun 2010 → Dec 2012 | colorectal carcinoma | Mologen AG | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02077868 | Sep 2014 → Feb 2019 | colorectal cancer | Mologen AG | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03837756 Comparator | May 2019 → Jul 2022 | HIV infectious disease | University of Aarhus | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lefitolimod | “The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based TLR9 agonist, might foster innate and adaptive immune response and thus improve immune-mediated control...” PMID 30137193 ↗ Oct 20184“DESIGN: This was an exploratory, single-arm clinical trial that tested the immune enhancement effects of 24-weeks of Toll-like receptor 9 (TLR9) agonist (MGN1703; Lefitolimod;...” PMID 30932955 ↗ Jul 2019 “TLR9 agonists, such as lefitolimod (MGN1703), significantly increased Th1 response in preclinical models and have demonstrated efficacy in early clinical trials.” PMID 39959251 ↗ Feb 2025 “a TLR9 agonist (lefitolimod) administered weekly between Weeks 24 and 33 (10 doses)” NCT04357821 ↗ |
| Known as | MGN1703 | “MGN1703 is being developed for use in treating cancerous tumors effecting the colon, skin, kidneys and lungs.” NCT01982747 ↗ |
| Known as | TLR9 AGONIST MGN1703 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297776 ↗ |
| Action | Activate | “a DNA-based TLR9 agonist” PMID 30137193 ↗ Oct 2018 |
| Modality | Oligonucleotide (other) | “a DNA-based TLR9 agonist” PMID 30137193 ↗ Oct 2018 |
| Route | Subcutaneous | “60mg MGN1703 as 2 s.c. injections” NCT01982747 ↗ |
| Target | TLR9 | “a DNA-based TLR9 agonist” PMID 30137193 ↗ Oct 2018 |